Prof. Dr. Gerhard Krönke

Medizinische Fakultät Professur für Modulation von Immunantworten Department of Medicine 3 – Rheumatology and Immunology

Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. (2023) Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, et al. Journal article, Erratum Soluble CD83 modulates human-monocyte-derived macrophages toward alternative phenotype, function, and metabolism. (2023) Peckert-Maier K, Wild A, Sprißler L, Fuchs M, Beck P, Auger JP, Sinner P, et al. Journal article Baricitinib Improves Bone Properties and Biomechanics in Patients With Rheumatoid Arthritis: Results of the Prospective Interventional BARE BONE Trial (2023) Simon D, Minopoulou I, Kemenes S, Bayat S, Tascilar K, Mutlu MY, Valor-Méndez L, et al. Journal article Neutrophils Regulate Bone Formation Via IL-1b Secretion (2022) Wakahashi K, Yu J, Rubio-Ponce A, Culemann S, Krishacoumar B, Scholtysek C, Krönke G, et al. Conference contribution CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients (2022) Müller F, Völkl S, Mougiakakos D, Böltz S, Aigner M, Gary R, Kretschmann S, et al. Conference contribution Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthritis by Using Magnetic Resonance Imaging (2022) Folle L, Bayat S, Kleyer A, Fagni F, Kapsner L, Schlereth M, Meinderink T, et al. Conference contribution, Abstract of a poster Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study (2022) Bayat S, Tascilar K, Bohr D, Krönke G, Simon D, Knitza J, Hartmann F, et al. Journal article Self-collection of capillary blood and saliva to determine COVID-19 vaccine immunogenicity in patients with immune-mediated inflammatory diseases and health professionals (2022) Schmetzer C, Vogt E, Stellar L, Godonou ET, Liphardt AM, Muehlensiepen F, Vuillerme N, et al. Journal article Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study) (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Mendez LV, Tascilar K, Krönke G, et al. Conference contribution CAR T Cell Treatment of Refractory Systemic Lupus Erythematosus (2022) Schett G, Böltz S, Müller F, Kleyer A, Völkl S, Aigner M, Gary R, et al. Conference contribution